Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

TECH

Bio-Techne

NASDAQ

Real-time Quotes | Nasdaq Last Sale

408.23

-14.82

-3.50%

After Hours: 408.23 0 0.00% 17:33 05/10 EDT

OPEN

421.13

PREV CLOSE

423.05

HIGH

423.30

LOW

407.91

VOLUME

259.22K

TURNOVER

52 WEEK HIGH

444.83

52 WEEK LOW

228.67

MARKET CAP

15.84B

P/E (TTM)

93.04

BRIEF-Bio-Techne Says Multisite Study Demonstrates Utility Of Asuragen Kit

reuters.com · 13h ago

Bio-Techne Provides an Update on its AmplideX

In the study, the AmplideX® Kit was evaluated independently at GenePhile Bioscience Laboratory in Taiwan; the University Medical Center Groningen in the Netherlands; Turku University Hospital

Benzinga · 14h ago

Multisite Study Demonstrates Utility of Asuragen Kit for Identifying Variants Linked to Spinal Muscular Atrophy

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, and scientific collaborators have published the results of a multisite evaluation study of the AmplideX PCR/CE SMA Plus* Kit that validates its perfo...

PR Newswire - PRF · 14h ago

DJ Bio-Techne Corporation CEO Chuck Kummeth on Q3 2021 Results -- Earnings Call Transcript >TECH

Dow Jones · 1d ago

10-Q: BIO-TECHNE CORP

(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management...

Edgar Online - (EDG = 10Q, 10K) · 3d ago

Growth of the Glycomics / Glycobiology Market to be Propelled by Proliferating Cancer and Diabetic Diseases by a Notable CAGR During 2020 - 2028

May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Glycomics / GlycobiologyMarket: Global Demand Analysis & Opportunity Outlook...

AmericaNewsHour · 3d ago

--Baird Adjusts Price Target on Bio-Techne to $430 From $410, Keeps Outperform Rating

MT Newswires · 3d ago

Glycomics / Glycobiology Market Size, Analysis, and Forecast Report 2028

May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Glycomics / Glycobiology Market: Global Demand Analysis & Opportunity...

AmericaNewsHour · 3d ago

Forecast

Actual (USD)

Estimate (USD)

Income StatementMore

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

Operating (USD)

YoY (%)

Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TECH stock price target is 453.89 with a high estimate of 500.00 and a low estimate of 410.00.

EPS

Institutional Holdings

Institutions: 578

Institutional Holdings: 39.29M

% Owned: 101.26%

Shares Outstanding: 38.80M

TypeInstitutionsShares

Increased

151

1.09M

New

1.07M

Decreased

145

2.18M

Sold Out

226.13K

Performance
Asset Allocation
Dividend History

No Data

Industry

Biotechnology & Medical Research

-2.01%

Pharmaceuticals & Medical Research

-0.44%

Key Executives

Chairman/Independent Director

Robert Baumgartner

President/Chief Executive Officer/Director

Charles Kummeth

Chief Financial Officer/Executive Vice President - Finance

James Hippel

Corporate Executive

David Eansor

Corporate Executive

Kim Kelderman

Senior Vice President/General Counsel/Secretary

Brenda Furlow

Independent Director

Julie Bushman

Independent Director

John Higgins

Independent Director

Joseph Keegan

Independent Director

Roeland Nusse

Independent Director

Alpna Seth

Independent Director

Randolph Steer

Independent Director

Rupert Vessey

Declaration Date Dividend Per Share Ex-Div Date: 05/06/2021
Dividend USD 0.32
05/14/2021; 02/02/2021
Dividend USD 0.32
02/11/2021; 11/05/2020
Dividend USD 0.32
11/13/2020; 08/04/2020
Dividend USD 0.32
08/17/2020; 04/30/2020
Dividend USD 0.32
05/08/2020; 02/04/2020
Dividend USD 0.32
02/13/2020; 10/29/2019
Dividend USD 0.32
11/07/2019; 08/06/2019
Dividend USD 0.32
08/15/2019; 04/30/2019
Dividend USD 0.32
05/09/2019; 02/05/2019
Dividend USD 0.32
02/14/2019; --
Dividend USD 0.32
11/08/2018; --
Dividend USD 0.32
08/16/2018; --
Dividend USD 0.32
05/11/2018; --
Dividend USD 0.32
02/15/2018; --
Dividend USD 0.32
11/09/2017; --
Dividend USD 0.32
08/16/2017; --
Dividend USD 0.32
05/17/2017; --
Dividend USD 0.32
02/15/2017; 10/31/2016
Dividend USD 0.32
11/09/2016; 08/17/2016
Dividend USD 0.32
08/25/2016; 04/26/2016
Dividend USD 0.32
05/11/2016; --
Dividend USD 0.32
02/10/2016; --
Dividend USD 0.32
11/10/2015; 08/06/2015
Dividend USD 0.32
08/13/2015; 05/05/2015
Dividend USD 0.32
05/13/2015; 02/03/2015
Dividend USD 0.32
02/11/2015; 10/30/2014
Dividend USD 0.32
11/06/2014; 08/11/2014
Dividend USD 0.31
08/19/2014; 04/28/2014
Dividend USD 0.31
05/07/2014; 02/04/2013
Dividend USD 0.31
02/12/2014; 10/31/2013
Dividend USD 0.31
11/07/2013; 08/06/2013
Dividend USD 0.3
08/14/2013; 04/30/2013
Dividend USD 0.3
05/08/2013; 02/05/2013
Dividend USD 0.3
02/13/2013; 10/26/2012
Dividend USD 0.3
11/01/2012; 07/31/2012
Dividend USD 0.28
08/08/2012; 05/01/2012
Dividend USD 0.28
05/09/2012; 01/31/2012
Dividend USD 0.28
02/08/2012; 10/27/2011
Dividend USD 0.28
11/03/2011; 08/02/2011
Dividend USD 0.27
08/10/2011; 05/03/2011
Dividend USD 0.27
05/11/2011; 02/01/2011
Dividend USD 0.27
02/09/2011; 10/28/2010
Dividend USD 0.27
11/04/2010; --
Dividend USD 0.26
08/12/2010; 05/04/2010
Dividend USD 0.26
05/12/2010; 02/02/2010
Dividend USD 0.26
02/10/2010; 10/29/2009
Dividend USD 0.26
11/05/2009; 08/04/2009
Dividend USD 0.25
08/13/2009; 04/28/2009
Dividend USD 0.25
05/06/2009; 02/03/2009
Dividend USD 0.25
02/11/2009

All
Financials
Insiders

About TECH

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.